Robert W. Baird Has Lowered Expectations for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its price target cut by research analysts at Robert W. Baird from $420.00 to $339.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price target suggests a potential upside of 33.89% from the stock’s current price.

COR has been the topic of several other research reports. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. JPMorgan Chase & Co. lifted their price target on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Wells Fargo & Company upped their price target on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Finally, Morgan Stanley set a $380.00 price objective on Cencora in a research note on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $391.83.

Cencora Stock Down 17.2%

Shares of NYSE:COR opened at $253.20 on Thursday. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. Cencora has a 52-week low of $244.82 and a 52-week high of $377.54. The business’s 50 day simple moving average is $330.01 and its two-hundred day simple moving average is $342.75. The firm has a market cap of $49.25 billion, a P/E ratio of 30.43, a PEG ratio of 1.43 and a beta of 0.64.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. During the same quarter in the prior year, the firm earned $4.42 EPS. The company’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts forecast that Cencora will post 17.58 EPS for the current fiscal year.

Institutional Investors Weigh In On Cencora

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its position in Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares during the period. AustralianSuper Pty Ltd purchased a new position in shares of Cencora during the third quarter valued at about $26,191,000. Mediolanum International Funds Ltd raised its stake in Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after buying an additional 32,138 shares in the last quarter. Chilton Investment Co. Inc. bought a new position in Cencora in the third quarter worth about $459,000. Finally, Advisors Asset Management Inc. lifted its holdings in Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after buying an additional 4,973 shares during the period. Institutional investors own 97.52% of the company’s stock.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Raised FY2026 EPS guide to $17.65–$17.90 and authorized a $1.0B share repurchase program — a shareholder-friendly move that supports EPS and signals confidence in execution. Seeking Alpha: FY2026 guidance & buyback
• Positive Sentiment: Quarterly dividend announced: $0.60 per share (record May 15, payable June 1), maintaining cash return to holders and modest yield (~0.9%).
• Neutral Sentiment: OneOncology integration and international operations boosted margins and operating income in parts of the business — evidence of profitable mix-shifts even as top-line growth cools. TipRanks: OneOncology contribution
• Neutral Sentiment: Company filed detailed results and slide deck — useful for drilling into segment trends and margin drivers. Business Wire: Q2 press release
• Negative Sentiment: Revenue missed consensus: Q2 revenue ~$78.4B vs. ~$81.1B expected; adjusted EPS $4.75 vs. ~$4.82 expected — the topline miss drove investor concern about sustainable growth. MSN: sales below estimates
• Negative Sentiment: Management trimmed revenue guidance for FY2026 (now ~$334.2B–$340.6B vs. street ~$345.9B), citing U.S. Healthcare Solutions headwinds: branded-drug price cuts, lower volumes to a large mail-order client and prior customer losses. That mix and client concentration risk were main drivers of the stock drop. Reuters: revenue outlook / U.S. segment headwinds
• Negative Sentiment: Market reaction: shares plunged (reports note ~17% intraday decline and a 52-week low) as investors prioritized the revenue miss, customer/GLP‑1 margin worries and negative operating cash flow despite better margins and higher EPS guidance. QuiverQuant: stock slide analysis
• Negative Sentiment: Insider selling and social-media chatter flagged concerns about customer losses and product-mix pressure — watch for continued sentiment-driven volatility and whether buybacks/guide lifts restore confidence. QuiverQuant: opinions & insider trading

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.